Importantly, improvement in inhibitor’s efficacy (IC50), selectivity of the target, and identification of therapeutic windows while taking cancers’ specific genotype and phenotype into account, are needed for SLC2A3 inhibitors to become effective anti-cancer therapeutics. This evidence concerns the gene SLC2A3 and cancer.